Delving into the Latest Updates on RQ-9 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

5-HT4 receptor

Action

agonists

Mechanism

5-HT4 receptor agonists(Serotonin 4 (5-HT4) receptor agonists)

Therapeutic Areas

Nervous System Diseases

Active Indication

Dementia

Inactive Indication

Alzheimer Disease

Originator Organization

RaQualia Pharma, Inc.

Active Organization

AskAt, Inc.

Inactive Organization

RaQualia Pharma, Inc.

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The aim of this study was to determine the cytotoxic properties, influence on enzyme activity involved in metabolic syndrome, and antimicrobial activity of synthetic peptides with GQLGEHGGAGMG, GEHGGAGMGGGQFQPV, EQGFLPGPEESGR, RLARAGLAQ, YGNPVGGVGH, and GNPVGGVGHGTTGT sequences. Peptides have no cytotoxic effect on cells. The highest inhibitory effect on angiotensin converting enzyme I was noted for peptide GT-14 (IC50 = 525.63 µg/mL). None of the tested peptides had an influence on α-glucosidase. The highest α-amylase and lipase inhibitory activity was noted for GG-12 (IC50 = 56.72 and 60.62 µg/mL, respectively). The highest lipoxidase inhibitory activity was determined for peptide ER-13 (IC50 = 84.35 µg/mL). Peptide RQ-9 was characterized by the highest COX inhibitory activity (0.31 and 4.77 µg/mL for COX-1 and COX-2, respectively). Only peptide RQ-9 inhibited S. enteritidis ATCC 4931 growth (42–48%) in all tested concentrations (15.62–250 mg/mL).

100 Deals associated with RQ-9

Login to view more data